Market
The latest in market for medical-aesthetics practice owners.
Market Daewoong's Nabota Hits 1 Trillion Won in Sales — Korean Toxin Maker Accelerates U.S. and Global Expansion
A third-party neuromodulator gains traction as price competition reshapes the toxin market.
Market GLP-1 Weight-Loss Boom Drives Post-Bariatric Body Contouring Surge — New Patient Pipeline for Medspas
Ozempic, Mounjaro adoption fuels demand for skin tightening and liposuction; practices report increased surgical referrals.
Market InMode Guides Q2 2026 Revenue to $95.2M–$95.4M; Full-Year Outlook Holds at $365M–$375M
Device maker reiterates FY guidance despite takeover bid uncertainty; Q2 results due August 5.
Market GLP-1 Weight-Loss Boom Drives Post-Reduction Body Contouring at Medspa Practices — New Revenue Stream Emerging
Practices are capitalizing on GLP-1 patient demand for non-surgical body tightening and skin quality treatments following significant weight loss.
Market GLP-1 Weight-Loss Boom Fuels Body-Contouring Volume — Practices Report Surge in Post-Weight-Loss Procedures
Ozempic/Wegovy patients driving demand for skin-tightening and body-sculpting treatments.
Market GLP-1 Weight Loss Boom Drives Post-Loss Body Contouring Demand at Aesthetic Practices
Ozempic and semaglutide uptake creates new patient flow for surgical and non-surgical body-sculpting procedures.
Market Fotona4D Reports Surge in Younger Patient Bookings — 'Collagen Banking' Becomes 2026 Trend
Preventive aesthetic procedures drive growth among Gen Z and younger millennials seeking early intervention.
Market Semaglutide Pricing at Medspas: Compounded vs. Branded and What Patients Actually Pay
Medspa semaglutide costs range from $200–$600+ per month depending on dose, formulation source, and markup strategy—here's how the margin model works and what drives patient pricing.
Market Semaglutide Face: Why Medspa Owners Should Offer Fillers to GLP-1 Patients
GLP-1 weight loss drives facial volume loss. Here's how to capture that filler revenue—and why patients are primed to buy.
Market Offering GLP-1 Weight Loss at a Medspa: Sourcing, Compliance, and Revenue Model
How to evaluate GLP-1 as a revenue line, navigate sourcing and prescriber requirements, and stay compliant with state and federal regulations.
Market GLP-1 Weight Loss Boom Drives 'Semaglutide Face' — Aesthetic Practices Report Surge in Volume Restoration Demand
Facial fat loss from GLP-1 drugs creates new patient cohort seeking filler and biostimulator treatments.
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.